CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Novavax rises after licensing deals boost annual revenue forecast

By Reuters News

** Vaccine maker Novavax's shares NVAX.O rise 2% to $10.86 premarket

** Co has relied on licensing deals and partnerships tied to its protein-based vaccine platform

** Co expects FY26 adj. revenue of $385 mln-$415 mln, up from $235 mln-$275 mln previously

** Loss-making co is banking on its licensing agreement with Sanofi SASY.PA, worth at least $1.2 bln, to reach profitability by 2028

** Sanofi plans a late-stage US trial of its influenza-COVID-19 combination vaccine in 2027; NVAX is eligible for a $225 mln milestone payment upon US commercial launch

** "We intend to bring new partners forward and it is core to our business model," CEO John Jacobs says

** Posts Q3 revenue of $68 mln, beating analysts' estimates of $50.4 mln, according to data compiled by LSEG

** Five of nine brokerages rate the stock "buy" or higher, one "hold" and three "sell" or lower; median PT is $11 - LSEG data

** As of last close, stock up 58.5% YTD

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.